Airway Auto Immunity in Asthma
Conditions
Keywords
auto immune, severe asthmatics, exacerbations, eosinophilic Asthma
Brief summary
It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics. There is increasing evidence that Airway auto immunity may be responsible for this poor response to treatment. It has been seen in earlier study done at Nair lab that these patients might benefit from Dupilumab, a biologic blocking IL-13/ IL-4. IL-13/IL-4 are the cytokines responsible for increased inflammation in these Asthmatics. The hypothesis is that blocking IL-13/IL-4 will also reduce the airway auto immunity which can be measured by comparing the auto immune markers in airway at baseline (before starting Dupilumab) and 16 weeks (after 4 months of Dupilumab treatment.
Detailed description
Asthma, a chronic airway disease characterized by reversible airflow, airway inflammation and hyper responsiveness. A prominent phenotype is eosinophilic asthma, with a prevalence rate of \ 50% and characterised by blood eosinophils \>300 cells/μL and sputum eosinophils \>3%. Inhaled corticosteroids (ICS) have been successful for treatment of mild-to-moderate asthma. However, \ 10% of eosinophilic asthmatics remain uncontrolled despite being on high dose oral corticosteroids. This small percentage contributes disproportionately to 80% of asthma healthcare costs \[8-10\]. As a steroid-sparing strategy, monoclonal antibody (mAb) therapies targeting interleukin (IL)-5 signalling have been developed that are projected to benefit this difficult-to-treat population. Yet, a subset (30-50%) of them remain symptomatic despite being on oral corticosteroids (OCS) and adjunct anti-IL-5 mAb. Anti- eosinophil peroxidase (EPX) Immunoglobulin G (IgG) levels in the airways strongly correlated with the presence of other auto antibodies, in particular the anti-nuclear antibodies (ANAs) as well as various clinical features of asthma severity. Therefore, a better understanding of the underlying pathology with subsequent identification of clinical/molecular biomarkers remains an unmet clinical need for optimal asthma management. Airway autoimmune responses in severe asthma is an important contributor to airway mucus and this can be ameliorated by blocking the IL-4/IL-13 inflammatory axis.
Interventions
None listed
Sponsors
Sanofi
McMaster University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
* Prior to the beginning of the study, patients must be willing and fully capable to provide written informed consent * Subjects must be able and willing to comply with the study protocol * Asthma diagnosed by a respiratory physician ≥ 36 months prior to study enrollment based on the Global Initiative for Asthma (GINA) 2014 guidelines * Patients referred or routinely followed for asthma by Dr. Nair * Clinical indication to prescribe dupilumab or will enter a clinical trial where patient will receive drug for at least 4 months * ICS dose ≥ 500 mcg of fluticasone equivalent/day, and/or daily prednisone
Exclusion criteria
* Current smoker defined as having smoked at least one cigarette (or pipe, cigar, or marijuana) per day for ≥ 30 days within the three months prior to screening * Ex-smokers with ≥ 20 pack-year smoking history * Current pregnancy or lactation * Treatment with anti- Immunoglobulin E (IgE), anti-IL-5, or anti-IL-5 Receptor targeted therapy currently or within three months prior to Visit 1 * Any prior medical conditions or treatment history that the physician deems unfit (including but not restricted to chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of severe asthmatics with a reduction in anti-EPX IgG in airway secretions (marker of airway autoimmunity) | 12 weeks | Reduction in anti-EPX IgG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the effect of dupilumab on luminal plugging (CT mucus score) and airway obstruction (FEV1) from baseline to post 4 months of therapy | 12 weeks | CT mucus score |
| To associate changes with respect to clinical indices of asthma control: blood eosinophils, fractional exhaled nitric oxide (FeNO) and asthma control questionnaire (ACQ) | 12 weeks | Blood eosinophil count |
| To determine the changes in sputum composition (sputum eosinophils, neutrophils, free eosinophil granules) and inflammatory mediators (eosinophil peroxidase, T2 cytokines and chemokines) from baseline to post 4 months of therapy | 12 weeks | Sputum cell differential count |
Countries
Canada
Outcome results
None listed